Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: May 17, 2011


Pacific Biosciences CSO Eric Schadt will become director of the Mount Sinai Institute for Genomics and Multiscale Biology as well as chairman of the department of genetics and genome sciences at Mount Sinai School of Medicine (see article, this issue). He will start at Mount Sinai in August and will remain PacBio's CSO. Schadt will succeed Joseph Buxbaum, the institute's interim director.

The National Academy of Sciences has elected 72 new members and 18 foreign associates from 15 countries, bringing its total number of active members 2,113 and the total number of foreign associates to 418.

Among those elected are George Church and David Bartel. Church invented multiplex sequencing and also founded the Personal Genome Project. He is a professor of genomics at Harvard Medical School, and has founded or advised more than 20 biotechnology companies, including Knome, Complete Genomics, and 23andMe.

David Bartel, professor of biology at the Whitehead Institute at MIT, is using sequencing to study small RNAs in plants and animals.

Daniel Bradbury and Roy Whitfield have been re-elected to serve on Illumina's board of directors for three years and Gerald Möller to serve on the board for two years. Bradbury has been a director of Illumina since 2004, while Whitfield has been a member of the board since 2007. Möller was named a director last year.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.